Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 15/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.68 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 3/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220061 | 0.88 | EGFR (0.79) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL31605602 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3DUS2 | |
| SCHEMBL2994028 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3DUS2 | |
| SCHEMBL4184896 | 0.85 | EGFR (0.78) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL25649216 | 0.83 | EGFR (0.78) | EGFRERBB2ERBB4ERBB3DUS2 | |
| SCHEMBL238877 | 0.83 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL29409571 | 0.83 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL29617536 | 0.81 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3DUS2 | |
| SCHEMBL21801932 | 0.81 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3DUS2 | |
| SCHEMBL29478966 | 0.81 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3DUS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| US-6602863-B1 | Irreversible inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20040198752-A1 | ADMINISTERING RETINOIDS WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | ELDER JAMES T (US) | 2004-10-07 | — | — | US | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| US-6602863-B1 | Irreversible inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | RARB, EBP, RXRA | EGFR 47/4885ERBB2 183/4885ERBB4 110/4885 |
| US-20040198752-A1 | ADMINISTERING RETINOIDS WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | EGFR, RARB, RXRA | EGFR 1/4885ERBB2 23/4885ERBB4 18/4885 |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.